Retrospective Analysis of the Pharmaco-Utilization of VEGF Inhibitors and Health Care Costs among Patients with Wet Age-Related Macular Degeneration and Other Ocular Diseases in Italy
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
This Italian retrospective study aimed to analyze the pharmaco-utilization of anti-VEGF drugs and health care costs among patients with wet age-related macular degeneration (wAMD) or other ocular diseases. A retrospective analysis was performed on administrative databases of Italian entities covering approximately six million individuals. Across January 2010–December 2017, patients aged ≥50 years with a prescription of intravitreal anti-VEGFs were included as “wAMD” patients [by wAMD hospitalization or intravitreal injections] or as “other ocular diseases” patients [by hospitalization for other ocular disorders or intravitreal injections, with concomitant diabetes diagnosis or dexamethasone treatment]. The date of first matching of inclusion criteria was index-date. wAMD-cohort. Overall, 3879 patients were included; at index-date, 82.2% were treated with Ranibizumab, 15.8% with Aflibercept, and 2% with Pegaptanib. During the follow-up, the mean/annual anti-VEGF prescription [3.6 (first-year)–0.8 (third-year)] and the total expenditure [5799.84 € (first-year)–3212.84 € (third-year)] decreased. Other ocular diseases-cohort. Overall, 2646 patients were enclosed; 85.9% were treated with Ranibizumab, 13.5% with Aflibercept, and 0.6% with Pegaptanib. During the follow-up, the mean/annual anti-VEGF prescription [3.3 (first-year)–0.5 (third-year)] and the total cost [7196.83 € (first-year)–5162.68 € (third-year)] decreased. This observational study highlighted a decline in anti-VEGF prescriptions over time in both cohorts, suggesting a trend of under-treatment that could worsen the patients’ clinical outcomes and increase health care resource consumption.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“On the other hand, a significant number of conditions, including nAMD, DR, DMO and macular oedema secondary to RVO and mCNV, are conditions for which anti-VEGF based treatments are indicated, but only a minority of this study’s results included costs of anti-VEGF injections (n = 9 [34–36, 48–50, 54–56]).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wong, W. L., Su, X., Li, X., Cheung, C. M. G., Klein, R., Cheng, C.-Y., & Wong, T. Y. (2014) · The Lancet Global Health · doi:10.1016/s2214-109x(13)70145-1 · Cited by 5,331 · cited 1×
“Worldwide estimates approximated that 30–50 million people are affected by AMD, and these numbers are expected to increase over time because of the aging population [5,6].”
BackgroundAge-related macular degeneration
Jager, R. D., Mieler, W. F., & Miller, J. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0801537 · Cited by 1,379
Age-related macular degeneration (AMD): pathogenesis and therapy.
Nowak, J. Z. (2006) · PubMed · Cited by 755
Holz, F. G., Tadayoni, R., Beatty, S., Berger, A., Cereda, M. G., Cortez, R., Hoyng, C. B., Hykin, P., Staurenghi, G., Heldner, S., et al. (2015) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305327 · Cited by 615 · cited 1×
“At the same time, the therapeutic management of wAMD patients and those with other ocular diseases requires monitoring visits, which are the most time and resource-consuming items of patient care, making monthly regimens unachievable in clinical practice [15,19,20].”
BackgroundPrevalence of Age-Related Macular Degeneration in Europe
Colijn, J. M., Buitendijk, G. H. S., Prokofyeva, E., Alves, D., Cachulo, M. L., Khawaja, A. P., Cougnard-Gregoire, A., Merle, B. M. J., Korb, C., Erke, M. G., et al. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.05.035 · Cited by 486
de Belvis, A. G., Meregaglia, M., Morsella, A., Adduci, A., Perilli, A., Cascini, F., Solipaca, A., Fattore, G., Ricciardi, W., Maresso, A., et al. (2014) · PubMed · Cited by 462
Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration
Ng, E. W. M., & Adamis, A. P. (2005) · Canadian Journal of Ophthalmology · doi:10.1016/s0008-4182(05)80078-x · Cited by 273 · cited 1×
“Elevated vascular endothelial growth factor (VEGF) levels have been shown to be implicated in the pathogenesis of wAMD [3,4].”
BackgroundFerrara, N. (2010) · Nature Medicine · doi:10.1038/nm1010-1107 · Cited by 203 · cited 1×
“Due to the recognition of the pathogenetic role of VEGF in ocular vascular diseases (including wAMD), the use of VEGF-specific antagonists (anti-VEGF) represents the current therapy [7], which demonstrated high rates of success in the clinical practice [7].”
BackgroundWykoff, C. C., Clark, W. L., Nielsen, J. S., Brill, J. V., Greene, L. S., & Heggen, C. L. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.2-a.s3 · Cited by 124
Khanna, S., Komati, R., Eichenbaum, D. A., Hariprasad, I., Ciulla, T. A., & Hariprasad, S. M. (2019) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2019-000398 · Cited by 124 · cited 1×
“In the registration trials for Ranibizumab and Aflibercept, after the first year of treatment, monthly (treatment every four weeks) and bimonthly (treatment every eight weeks after 3-month loading) fixed regimens were used, respectively [10].”
Method
Research works printed but not linked: 2
- Marcianò, I., Giorgianni, F., and Aliquò, I. (2017, January 25–28). Intravitreal anti-VEGF injections: Real-world data on the pattern of use using multiple administrative healthcare databases from Southern Italy. Proceedings of the 38th Congress of the Italian Pharmacological Society (SIF), Rimini, Italy.
- Barzey, V., Muston, D., Gerlinger, C., and Lloyd, A. (2015, January 22–24). Relationship between visual acuity and ability to perform activities in patients with diabetic macular edema. Proceedings of the 15th ESASO Retina Academy 2015, Barcelona, Spain.
Cited by
Hashimoto, Y., Okada, A., Matsui, H., Yasunaga, H., Aihara, M., & Obata, R. (2022) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-022-00969-2 · Cited by 46
“Trends in the use of anti-VEGF are reported in various countries, the US [14, 15], the UK [16], and Italy [17].”
BackgroundLupidi, M., Iaculli, C., Marco, L., Rossi, S., Sicari, E., Villa, G., & Pirani, V. (2025) · Ophthalmology and Therapy · doi:10.1007/s40123-025-01204-0 · Cited by 8
Chen, X., Bian, H., & Wu, Z. (2025) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-025-00909-x · Cited by 2
The retinal neurovascular coupling is impaired in men with vasculogenic erectile dysfunction
Borrelli, E., Quarta, A., Pozzi, E., Fallara, G., Pennisi, F., Casaluci, M., Lamanna, F., Querques, L., Sacconi, R., Bandello, F. M., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-35339-6 · Cited by 2
Li, J., Ma, Y., Hu, M., Zhang, Q., Wang, A., Tang, Q., Guo, Q., & Huang, B. (2026) · Genetics Research · doi:10.1155/genr/8903808 · Cited by 1
Metadata
- Authors
- Perrone, V., Dovizio, M., Veronesi, C., Citraro, R., De Francesco, A., Dell’Orco, S., Di Manno, G., Paciello, A., Resta, A. M., Quarta, F., Ferrante, N., Ritrovato, D., & Degli Esposti, L.
- Affiliations
- CliCon S.r.l. Società Benefit Health, Economics & Outcomes Research, 40121 Bologna, Italy
- Magna Graecia University (IT)
- Unita’ Operativa di Farmacologia Clinica e Farmacovigilanza, Azienda Ospedaliero-Universitaria “Mater Domini”, Università Magna Grecia di Catanzaro, 88100 Catanzaro, Italy
- Azienda Sanitaria Locale (ASL) Roma 6, Albano Laziale, 00100 Rome, Italy
- Agenzia di Tutela della Salute (ATS) Bergamo, 24100 Bergamo, Italy
- Struttura Complessa di Farmacia Territoriale Area Vasta 1, 61032 Fano, Italy
- U.O. Epidemiologia e Statistica, Azienda Sanitaria Locale (ASL) Lecce, 73100 Lecce, Italy
- Novartis (Italy) (IT)
- Corresponding author
- Perrone, Valentina
- ORCID
- Venue
- International Journal of Environmental Research and Public Health
- Publisher
- MDPI AG
- Published
- 2022-02-23
- Volume
- 19
- Issue
- 5
- Pages
- 2548
- ISSN
- 1660-4601 (ISSN-L)
- PMC
- PMC8909764
- OpenAlex
- W4214662097
- Cited by
- 8
- References
- 19
- Citations by year
- 2026: 2 · 2025: 3 · 2023: 2 · 2022: 1
- FWCI
- 1.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Environmental Research and Public Health (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Novartis Farma (N/A)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Keywords
- VEGF inhibitors, neovascular age-related macular degeneration, eye diseases, health care costs, intravitreal injection, ranibizumab, aflibercept, pegaptanib, prescribing trends, undertreatment, Italy
- MeSH terms
- Ranibizumab, Antibodies, Monoclonal, Humans, Retrospective Studies, Health Care Costs, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Wet Macular Degeneration
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Retrospective Analysis of the Pharmaco-Utilization of VEGF Inhibitors and Health Care Costs among Patients with Wet Age-Related Macular Degeneration and Other Ocular Diseases in Italy. https://app.cochat.ai/papers/10.3390/ijerph19052548
- The paper
- Perrone, V., Dovizio, M., Veronesi, C., Citraro, R., De Francesco, A., Dell’Orco, S., Di Manno, G., Paciello, A., Resta, A. M., Quarta, F., Ferrante, N., Ritrovato, D., & Degli Esposti, L. (2022). Retrospective Analysis of the Pharmaco-Utilization of VEGF Inhibitors and Health Care Costs among Patients with Wet Age-Related Macular Degeneration and Other Ocular Diseases in Italy. International Journal of Environmental Research and Public Health. https://doi.org/10.3390/ijerph19052548
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.